Use of Interleukin-2 in the Management of Haematological Malignancies: Focus on Minimal Residual Disease

Author： Mandelli F.   Capria S.   Vignetti M.   Meloni G.  

Publisher： Adis International

ISSN： 1173-8804

Source： BioDrugs, Vol.12, Iss.1, 1999-07, pp. : 43-53

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Monoclonal Antibody Therapy of Haematological Malignancies

By Dearden C.  

BioDrugs, Vol. 16, Iss. 4, 2002-01 ,pp. : 283-301

Adis International

Access to resources Recommend Favorite

Minimal Residual Disease in Acute Myeloid Leukemia: Still a Work in Progress?

By Mosna Federico   Capelli Debora   Gottardi Michele  

Journal of Clinical Medicine, Vol. 6, Iss. 6, 2017-06 ,pp. : 57-57

MDPI

Access to resources Recommend Favorite

When Less Is Good, Is None Better? The Prognostic and Therapeutic Significance of Peri-Transplant Minimal Residual Disease Assessment in Pediatric Acute Lymphoblastic Leukemia

By Lamble Adam   Phelan Rachel   Burke Michael  

Journal of Clinical Medicine, Vol. 6, Iss. 7, 2017-07 ,pp. : 66-66

MDPI

Access to resources Recommend Favorite

Use of Interleukin-2 in Immunotherapy of Human Immunodeficiency Virus Infection

By Reier A.   Mitsuyasu R.T.  

BioDrugs, Vol. 10, Iss. 3, 1998-09 ,pp. : 215-225

Adis International

Access to resources Recommend Favorite

Interleukin-2 in Cancer Therapy: Uses and Optimum Management of Adverse Effects

By Mekhail T.   Wood L.   Bukowski R.  

BioDrugs, Vol. 14, Iss. 5, 2000-11 ,pp. : 299-318

Adis International

Access to resources Recommend Favorite